Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Restless Legs Syndrome

Interventions

DRUG: IPX159
DRUG: Placebo

Sponsor

Impax Laboratories, LLC